Semaglutide 2.4 mg produces weight-independent liver benefits among individuals with metabolic dysfunction-associated steatohepatitis.
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback